Company Overview and News

to your dashboard

Headline News

The Top 10 Value Stocks in the S&P 500

2018-01-19 investorplace
“Value will have its day in the sun.” That’s what John Buckingham, a veteran value investor and chief investment officer at AFAM Capital Asset Management, recently told Kiplinger in an interview. (264-1)

Wall Street Is Increasingly Bullish on ABT ahead of 4Q17 Results

On January 24, 2018, Abbott Laboratories (ABT) will announce its 4Q17 and full fiscal 2017 earnings results. The company registered strong results in fiscal 3Q17, surpassing analysts’ estimates. In this article, let’s take a look at the recent Wall Street analyst recommendations on ABT stock. (71-0)

JNJ Stock ahead of Its 4Q17 Results: Analyst Recommendations

Johnson & Johnson (JNJ) is set to announce its fiscal 4Q17 and fiscal 2017 earnings results on January 23, 2018. The company reported strong earnings results in fiscal 3Q17, surpassing the analysts’ sales as and EPS (earnings per share) estimates. (35-0)

Vilas Fund Partner Up 65% In 2017: Short Tesla Inc. Is Now Largest Holding

2018-01-11 seekingalpha
Before we begin the discussion of performance, we would like to remind our investors that we use a concentrated value approach to our investments, which primarily includes equities but has included bonds as well. The goal of the Vilas Fund, LP is to produce long-term returns that exceed equity market averages by a material amount, net of fees. To accomplish this goal, we are willing to tolerate both the markets going up and down as well as our strategy going in and out of favor. (210-0)

Stryker Announces Preliminary 4Q17 and Fiscal 2017 Results

On December 9, Stryker (SYK) announced the preliminary results for its 4Q17 and fiscal 2017 earnings results ahead of its quarterly earnings release on January 30. On December 9, SYK stock price fell approximately 1.4%. However, the stock traded at a 52-week high of $164.2. The Vanguard S&P 500 ETF (VOO) registered a rise of ~0.36% in its price on December 9. SYK makes up ~0.23% of VOO’s total portfolio holdings. (71-0)

Stryker’s Stock Rally Continues with 52-Week High Yesterday

On January 9, Stryker (SYK) traded at a 52-week high of $164.2 per share. The stock ended trading with a closing price of $160.4. As of January 9, 2018, SYK stock is trading higher than its 50-day moving average of $155 as well as the 200-day moving average of $148.1. Stryker traded at a 52-week low of $117.6 on January 9, 2017. The company’s one-year stock return is ~35% as of January 9, 2018. (7-0)

FDA Nod for Zimmer Biomet's Sidus, Aids Arthroplasty Arm

2018-01-08 zacks
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) reached a new milestone in the field of total shoulder arthroplasty with the recent Food and Drug Administration (FDA) approval for its SidusStem-Free Shoulder system in the United States. Following this approval, the Sidus system will be available in the country from the first quarter of 2018. This total shoulder arthroplasty solution claims to benefit patients with a good bone stock and also at the same time, complaining of either osteoarthritis, post-traumatic arthrosis, focal avascular necrosis of the humeral head or for those having undergone previous surgeries of the shoulder that do not compromise the fixation. (27-0)

Broadfin Capital, LLC - All Holdings - 13F 13D 13G Filings -

Broadfin Capital, LLC has disclosed 45 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 676,005,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Broadfin Capital, LLC's top holdings are Heron Therapeutics, Inc. (NASDAQ:HRTX) , Corium International, Inc. (NASDAQ:CORI) , Retrophin, Inc. (NASDAQ:RTRX) , Horizon Pharma plc (NASDAQ:HZNP) , and Flamel Technologies S. (149-0)

Zimmer Biomet on the Street: How the Analysts Are Leaning

2018-01-03 marketrealist
Zimmer Biomet Holdings (ZBH) is one of the major medical device players in the United States and has a leading portfolio of musculoskeletal products. But it announced disappointing 3Q17 earnings results on November 1, 2017, and lowered its fiscal 2017 guidance. (97-1)

Align Technology’s Growth Prospects amid Increasing Competition

2018-01-02 marketrealist
Align Technology (ALGN) is growing at an accelerated pace with its market-leading Invisalign clear aligners. The company generates revenues through two segments: Clear Aligner and Scanner & Services. (34-0)

New Strong Sell Stocks for December 27th

2017-12-27 zacks
NetEase, Inc. (NTES - Free Report) is an operator of an interactive online community. The Zacks Consensus Estimate for its current year earnings has been revised 2% downward over the last 30 days. (27-0)

Blog Exposure - Zimmer Biomet Announced Publication of Positive Results from PROGRESS II Trial of nSTRIDE® APS Kit for Knee Osteoarthritis Treatment

2017-12-27 accesswire
LONDON, UK / ACCESSWIRE / December 27, 2017 / has just released a free research report on Zimmer Biomet Holdings, Inc. (NYSE: ZBH). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On December 22, 2017, the Company declared that it has published positive results from PROGRESS II trial, demonstrating the safety and efficacy of the nSTRIDE® Autologous Protein Solution (APS) Kit, prepared by using Zimmer Biomet's nSTRIDE APS Kit, for the treatment of knee osteoarthritis (OA). (29-0)

Discussing the Recent Management Changes at Medtronic

2017-12-26 marketrealist
Recently, Medtronic (MDT) underwent a series of management changes, as the vice president of the company’s minimally invasive therapies group (or MITG), Bryan Hanson, left to join Zimmer Biomet Holdings (ZBH) as the CEO. Medtronic’s business groups are shown in the chart below. (21-0)

Zimmer Biomet Suffers a Dull Knee Business & Supply Delay

2017-12-26 zacks
On Dec 22, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH - Free Report) . The company carries a Zacks Rank #4 (Sell). (75-0)

Zimmer Biomet Strong on Positive Data From PROGRESS II Study

2017-12-26 zacks
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) recently announced positive results from PROGRESS II for treatment of knee osteoarthritis (OA). Data from the study (based on 46 patients with symptomatic knee OA pain from the four trial sites across Europe) demonstrated the safety and efficacy of the nSTRIDE Autologous Protein Solution (APS) Kit for the therapy. (76-0)

CUSIP: 98956P102